Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL
Patients were randomly assigned (1:1) to receive either 6 cycles of FCR every 28 days or IR for up to 6 years.
ASH 2021
Conference Coverage
Educational Burdens for Children With Sickle Cell Disease in the US Vs Other Nations
Researchers sought to determine the educational burdens of children with SCD in the US compared with other nations.
Prediction Model Identifies Patients With Unprovoked Venous Thromboembolism at Low Risk of Recurrence
Researchers sought to create a prediction model to identify patients with unprovoked venous thromboembolism who are at low risk of recurrence.
COVID-19 Vaccination Safe, Effective for Transfusion-Dependent Patients With Beta-Thalassemia
Researchers sought to determine whether the COVID-19 mRNA vaccines were safe and effective in patients with transfusion-dependent beta-thalassemia.
Outcomes in Nontransfusion-Dependent β-Thalassemia With Luspatercept or Placebo
Researchers sought to determine whether luspatercept would improve outcomes in patients with nontransfusion-dependent β-thalassemia.
Sutimlimab Appears Safe and Efficacious in Patients With Cold Agglutinin Disease
Researchers sought to determine whether sutimlimab would be safe and effective in treating patients with cold agglutinin disease.
Clonal Hematopoiesis of Indeterminate Potential Associated With Reduced Risk of Alzheimer’s Disease
Researchers sought to determine whether there was an association between the presence of clonal hematopoiesis of indeterminate potential and protection from Alzheimer’s disease.
Conditioning Regimens Prior to Autologous Transplantation for Multiple Myeloma
A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.
Adding Pevonedistat to Azacitidine Does Not Improve Outcomes for Patients With MDS/CMML and AML
Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.
Pegcetacoplan Improves Outcomes Compared With Standard of Care in Patients With Paroxysmal Nocturnal Hemoglobinuria
Researchers sought to determine whether pegcetacoplan would be better than standard of care for treating patients with PNH.
Adding Elotuzumab to Myeloma Treatment Regimens Does Not Improve Outcomes
Predictors of worse progression-free survival included ISS stage II, ISS stage III, and adverse cytogenetics.
Fitusiran Prophylaxis Improves Annualized Bleeding Rate in Hemophilia A and B
Researchers sought to determine whether fitusiran prophylaxis would reduce the rate of bleeding events among patients with hemophilia A or B with inhibitors.
Guadecitabine Is Not Superior to Treatment Choice in Patients With Pretreated Acute Myeloid Leukemia
Researchers sought to determine whether guadecitabine would have an overall survival benefit for patients with relapsed/refractory acute myeloid leukemia.
Low-Dose Inotuzumab Ozogamicin May Be Safe and Effective in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Researchers sought to determine whether a low dose of inotuzumab ozogamicin would be safe and effective in patients with relapsed/refractory ALL.
CAR-T Therapy May Improve Outcomes in Second-Line Relapsed/Refractory LBCL
Researchers sought to determine whether lisocabtagene maraleucel would improve outcomes compared with standard of care in second-line therapy in patients with LBCL.
Treatment With Azacitidine, Lenalidomide and Donor Lymphocyte Infusion in Myeloid Malignancies After Relapse Following Allo-SCT
Patients received up to 8 cycles of AZA and up to 3 cycle of DLI with increasing T cell dosages.
Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
COVID-19 Vaccination Does Not Increase Deep Vein Thrombosis Risk
Researchers sought to determine whether vaccination against COVID-19 would increase the risk of developing deep vein thrombosis.
Mesenchymal Stromal Cells Plus Second-Line Therapy Appears Efficacious in Steroid-Resistant Acute Graft-vs-Host Disease
The study included 203 patients with steroid-resistant acute GVHD who were treated at 10 centers in China between September 2014 and March 2019.
Want to read more?
Please login or register first to view this content.